Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
Conditions: Esophageal Squamous Cell Carcinoma; Neoadjuvant Chemoimmunotherapy; Adjuvant Therapy Intervention: Drug: Tislelizumab Sponsor: Guo Xufeng Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus
Condition: Solid Tumor, KRAS Mutation Intervention: Drug: BI 3706674 Sponsor: Boehringer Ingelheim Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
Conditions: Esophageal Squamous Cell Carcinoma; Neoadjuvant Chemoimmunotherapy; Adjuvant Therapy Interventions: Drug: Tislelizumab Sponsors: Guo Xufeng Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus
Conditions: Solid Tumor, KRAS Mutation Interventions: Drug: BI 3706674 Sponsors: Boehringer Ingelheim Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors
Condition: PARP Inhibitor for Esophageal Squamous Cell Carcinoma Intervention: Drug: Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm)) Sponsor: Chongqing University Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors
Conditions: PARP Inhibitor for Esophageal Squamous Cell Carcinoma Interventions: Drug: Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm)) Sponsors: Chongqing University Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+/3+ ESCC
Conditions: Esophageal Squamous Carcinoma; HER-2 Protein Overexpression Interventions: Drug: RC48+PD-1+platinum-based Sponsors: Changhai Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
Condition: Esophageal Squamous Cell Carcinoma Interventions: Drug: Carrelizumab; Drug: Paclitaxel injection; Drug: Cisplatin; Radiation: Concurrent chemoradiotherapy Sponsor: The First Affiliated Hospital with Nanjing Medical University Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age
Condition: Esophageal Carcinoma Interventions: Drug: Nimotuzumab; Drug: Tigio; Radiation: Concurrent radiation therapy Sponsor: The First Affiliated Hospital with Nanjing Medical University Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Follow-up Strategy for Esophageal Cancer Patients
Condition: Esophagus Cancer Intervention: Other: follow-up with different time intervals Sponsor: Sun Yat-sen University Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Adenocarcinoma
Conditions: Adenocarcinoma Esophagus; Locally Advanced Adenocarcinoma; Siewert Type I Adenocarcinoma of Esophagogastric Junction; Siewert Type II Adenocarcinoma of Esophagogastric Junction Interventions: Drug: Vactosertib; Drug: Standard of Care Chemotherapy; Radiation: Concurrent Radiation Sponsor: Jennifer Eva Selfridge Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
Condition: Esophageal Squamous Cell Carcinoma Interventions: Drug: Carrelizumab; Drug: Paclitaxel injection; Drug: Cisplatin; Radiation: Concurrent chemoradiotherapy Sponsor: The First Affiliated Hospital with Nanjing Medical University Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age
Condition: Esophageal Carcinoma Interventions: Drug: Nimotuzumab; Drug: Tigio; Radiation: Concurrent radiation therapy Sponsor: The First Affiliated Hospital with Nanjing Medical University Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
